Original Article|Articles in Press

Usefulness of texture and color enhancement imaging in assessing mucosal healing in patients with ulcerative colitis

Published:November 29, 2022DOI:

      Background and aims

      Endoscopic remission is known to be defined as a Mayo endoscopic subscore (MES) of ≤1 in patients with ulcerative colitis (UC). However, some individuals experience relapse even after showing endoscopic remission under white-light imaging (WLI), and no tool exists that can detect these individuals. The aim of this study was to clarify the usefulness of texture and color enhancement imaging (TXI) in the assessment of inflammation in patients with UC.


      This was a prospective, single-arm, observational study conducted at a university hospital. From January 2021 to December 2021, 146 UC patients with endoscopic remission were enrolled. Images were evaluated by WLI, TXI, and pathologic evaluation, followed by prognostic studies. The primary endpoint of the study was the cumulative relapse of UC in each TXI score. The secondary endpoints were the association between TXI and pathologic scores, predictors of relapse, and interobserver agreement between the MES and TXI scores.


      Patients with TXI score 2 had significantly lower UC relapse-free rates than did those with TXI scores 0-1 (log-rank test, P < .01). When pathologic remission was defined as Matts grade ≤2, the rate of pathologic remission decreased significantly with higher TXI scores (P = .01). In multivariate analysis, TXI score 2 was the only risk factor for UC relapse (P < .01; hazard ratio, 4.16; 95% confidence interval, 1.72-10.04). Interobserver agreement on the TXI score was good (κ = 0.597-0.823).


      TXI can be used to identify populations with poor prognosis in MES 1, for whom treatment intensification has been controversial.


      MES (Mayo endoscopic subscore), TXI (texture and color enhancement imaging), UC (ulcerative colitis), WLI (white-light imaging)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gastrointestinal Endoscopy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Fumery M.
        • Singh S.
        • Dulai P.S.
        • et al.
        Natural history of adult ulcerative colitis in population-based cohorts: a systematic review.
        Clin Gastroenterol Hepatol. 2018; 16: 343-356.e3
        • Rutter M.D.
        • Saunders B.P.
        • Wilkinson K.H.
        • et al.
        Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk.
        Gut. 2004; 53: 1813-1816
        • Frøslie K.F.
        • Jahnsen J.
        • Moum B.A.
        • et al.
        Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort.
        Gastroenterology. 2007; 133: 412-422
        • Colombel J.F.
        • Rutgeerts P.
        • Reinisch W.
        • et al.
        Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis.
        Gastroenterology. 2011; 141: 1194-1201
        • Rutgeerts P.
        • Sandborn W.J.
        • Feagan B.G.
        • et al.
        Infliximab for induction and maintenance therapy for ulcerative colitis.
        N Engl J Med. 2005; 353: 2462-2476
        • Peyrin-Biroulet L.
        • Sandborn W.
        • Sands B.E.
        • et al.
        Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target.
        Am J Gastroenterol. 2015; 110: 1324-1338
        • Barreiro-de Acosta M.
        • Vallejo N.
        • de la Iglesia D.
        • et al.
        Evaluation of the risk of relapse in ulcerative colitis according to the degree of mucosal healing (Mayo 0 vs 1): a longitudinal cohort study.
        J Crohns Colitis. 2016; 10: 13-19
        • Kim J.H.
        • Cheon J.H.
        • Park Y.
        • et al.
        Effect of mucosal healing (Mayo 0) on clinical relapse in patients with ulcerative colitis in clinical remission.
        Scand J Gastroenterol. 2016; 51: 1069-1074
        • Viscido A.
        • Valvano M.
        • Stefanelli G.
        • et al.
        Systematic review and meta-analysis: the advantage of endoscopic Mayo score 0 over 1 in patients with ulcerative colitis.
        BMC Gastroenterol. 2022; 22: 92
        • Dobashi A.
        • Ono S.
        • Furuhashi H.
        • et al.
        Texture and color enhancement imaging increases color changes and improves visibility for squamous cell carcinoma suspicious lesions in the pharynx and esophagus.
        Diagnostics (Basel). 2021; 11: 1971
        • Abe S.
        • Makiguchi M.E.
        • Nonaka S.
        • et al.
        Emerging texture and color enhancement imaging in early gastric cancer.
        Dig Endosc. 2022; 34: 714-720
        • Takabayashi K.
        • Kato M.
        • Sugimoto S.
        • et al.
        Texture and color enhancement imaging combination with indigo carmine dye spraying highlighted the border of flat ulcerative colitis-associated neoplasia.
        Gastrointest Endosc. 2022; 95: 1273-1275
        • Lai E.J.
        • Calderwood A.H.
        • Doros G.
        • et al.
        The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented research.
        Gastrointest Endosc. 2009; 69: 620-625
        • Schroeder K.W.
        • Tremaine W.J.
        • Ilstrup D.M.
        Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomized study.
        N Engl J Med. 1987; 317: 1625-1629
        • Matts S.G.
        The value of rectal biopsy in the diagnosis of ulcerative colitis.
        Q J Med. 1961; 30: 393-407
        • Neurath M.F.
        • Travis S.P.
        Mucosal healing in inflammatory bowel diseases: a systematic review.
        Gut. 2012; 61: 1619-1635
        • Zenlea T.
        • Yee E.U.
        • Rosenberg L.
        • et al.
        Histology grade is independently associated with relapse risk in patients with ulcerative colitis in clinical remission: a prospective study.
        Am J Gastroenterol. 2016; 111: 685-690
        • Bryant R.V.
        • Burger D.C.
        • Delo J.
        • et al.
        Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalisation over 6 years of follow-up.
        Gut. 2016; 65: 408-414